researcher

Professor Brian Lithgow

BSc, BE, M.Eng.Sc (Melbourne)

Inventor, Chief Scientific Officer and Principal Investigator

Brian is currently the Leader of the research programs in Australia and Canada. 

He is an Adjunct Professor at the University of Manitoba, Riverview Health Centre, Diagnostic (Neurosignal Processing Research Lab) in Winnipeg Canada, where Neural Diagnostics has funded its first international EVestG™ facility. The Canada facility research foci are to: (1) discover and validate biomarkers that differentiate Alzheimer’s disease from other dementias, monitor the efficacy of rapid trans cranial stimulation (rTMS) to treat AD and predict the efficacy of rTMS for individual AD sufferers. (2) discover and validate biomarkers that differentiate detect post-concussion syndrome (PCS) from controls, monitor the efficacy of rapid trans cranial stimulation (rTMS) to treat PCS and measure the recovery from PCS.

Brian is also an Adjunct Associate Professor at Monash Alfred Psychiatry Research Centre at the Alfred Hospital in Melbourne. In Melbourne the research foci were to: (1) discover and validate biomarkers that both detect and differentiate Major Depressive Disorder from Bipolar Disorder and from other psychiatric conditions and to monitor the efficacy of (rTMS) to treat Depression. (2) Discover and validate biomarkers that differentiate detect pre-and post LDopa treated Parkinson’s Disease (PD) patients from controls and in the process monitor end dose effects of LDopa. 

Previously, Brian previously worked for Industry including as Deputy Director of Biomedical Engineering at the Alfred Hospital. He was also a full time academic at Monash University for 26 years.

His research interests focus on Vestibular neurophysiology and modelling Neuropsychiatric and Neurodegenerative diagnostics, the physiology behind neuro-diagnostic biomarkers and the application of advanced time-frequency and statistical signal processing techniques to biological signals.

His publications include more than 120 refereed publications, four patents, two book chapters and six books. He has held various large Australian and Canadian competitive and Industrial grants totalling many millions. He has also supervised many successful PhD studies in both Australia and Canada.

WHAT WE'RE DIAGNOSING

NOW:

  • MAJOR DEPRESSIVE DISORDER (DEPRESSION)

  • BIPOLAR AFFECTIVE DISORDER (BIPOLAR)

  • DEPRESSION FROM BIPOLAR

  • LDOPA EFFICACY IN PARKINSON'S DISEASE

  • POST-CONCUSSIVE SYNDROME (INCLUDING SEVERITY &
    R-TMS TREATMENT EFFICACY)

  • ALZHEIMER'S DISEASE

 

IN DEVELOPMENT:

  • PREDICTIVE MEDICATION SELECTION FOR DEPRESSION

  • DEMENTIA—SEPARATION OF DEMENTIA TYPE & PREDICTING R-TMS TREATMENT EFFICACY

  • MILD TRAUMATIC BRAIN INJURY / CONCUSSION

  • ANXIETY MEASURES

  • VISUAL IMPACT ON THE VESTIBULAR SYSTEM (CONVERGENCE INSUFFICIENCY)

  • VERTIGINOUS DISORDERS (MENIERE'S DISEASE)

  • SCHIZOPHRENIA